{{Rsnum
|rsid=3731217
|Gene=CDKN2A
|Chromosome=9
|position=21984662
|Orientation=minus
|GMAF=0.152
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=CDKN2A
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 1.8 | 23.9 | 74.3
| HCB | 2.9 | 33.8 | 63.2
| JPT | 6.2 | 29.2 | 64.6
| YRI | 0.0 | 19.7 | 80.3
| ASW | 0.0 | 26.3 | 73.7
| CHB | 2.9 | 33.8 | 63.2
| CHD | 5.5 | 33.9 | 60.6
| GIH | 1.0 | 18.8 | 80.2
| LWK | 0.0 | 14.5 | 85.5
| MEX | 0.0 | 25.9 | 74.1
| MKK | 1.3 | 19.2 | 79.5
| TSI | 2.0 | 33.3 | 64.7
| HapMapRevision=28
}}{{omim
|desc=CYCLIN-DEPENDENT KINASE INHIBITOR 2A; CDKN2A
|id=600160
|rsnum=3731217
}}
{{PMID Auto
|PMID=21061336
|Title=p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck
}}

{{PMID Auto
|PMID=20453839
|Title=Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.
|OA=1
}}

{{PMID Auto
|PMID=20919861
|Title=Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence.
}}

{{PMID Auto
|PMID=21381012
|Title=p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.
|OA=1
}}

{{PMID Auto
|PMID=24104554
|Title=Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy
}}

{{PMID Auto
|PMID=23218882
|Title=Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}